AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation
Fort Worth, Texas, April 18, 2019 – Phyton Biotech, a German/North American Plant Cell Fermentation (PCF®) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, are pleased to announce today that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVida’s paclitaxel injectable FDF.
Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF® technology process. Under the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida’s Taxol generic formulation, which is produced in AqVida’s new state-of-the-art injectable manufacturing facility located in Dassow, Germany. AqVida’s ultramodern robotic manufacturing line, designed for filling cytotoxic injectables, will be utilized to produce AqVida’s generic oncology medicines to treat common types of cancer.
“We chose to work with Phyton because of the company’s superior quality fermentation-produced API, in comparison to naturally extracted or semi-synthetically produced alternatives,” says Wolfgang Heinze, who is the Chief Executive Officer (CEO) of AqVida. “Approval of ourpaclitaxel injectable FDF by the European Directorate of Quality Medicines is a major milestone for our company.”
Recognized for its innovative and broad portfolio of generic oncology medicines, AqVida is a leading German oncology medication supplier that distributes its products globally.
“We are proud to partner with AqVida and assist with the expansion of its oncology product line,” says Colin Marr, president of Phyton Biotech. “Phyton is committed to working with trusted pharmaceutical partners who seek to improve the quality of oncology medicines.”
About Phyton Biotech
Phyton Biotech, a wholly-owned subsidiary of DFB Pharmaceuticals, is the global leader in Plant Cell Fermentation (PCF®) Technology, offering comprehensive services for the development and commercialization of plant-based molecules, extracts and recombinant products, serving the pharmaceutical, Chinese Traditional Medicine, Cosmetic, Agricultural and Food Ingredient industries. Using PCF®, Phyton Biotech offers a time-, risk- and cost-balanced path to commercially viable production processes, overcoming limitations often experienced with traditional plant extraction and chemical synthesis.
As a biotechnology leader with certified GMP facilities in Germany and Canada, Phyton Biotech has a successful track record of developing and implementing innovative contract development solutions for clients around the world. The company is now the world’s largest producer of paclitaxel and docetaxel via PCF®, with the capacity to meet more than one-third of the global demand for these critical active pharmaceutical ingredients. For more information, please visit phytonbiotech.com.
AqVida is a German pharmaceutical manufacturer of injectable finished dosage formulation (FDF) medications. Its mission is fully dedicated to, and specialized in, the development, registration, manufacturing and distribution of injectable FDF mainly for the oncology sector. It has developed a portfolio of injectable generic oncology medicines for treating the most common types of cancer. AqVida’s expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry.